Babies, antiretroviral drugs, heart trouble
Posted by Henry Bauer on 2014/03/06
“HIV” is held responsible for innumerable ills labeled “HIV-associated” (4.3.4 in The Case against HIV), essentially anything that produces a positive “HIV” test-result. Of such false-positive “HIV” test-results there are scores of examples (3.1.7.3, 3.1.8, 3.2 in The Case against HIV).
Many of the published articles fail to specify whether or not the described patients were on antiretroviral treatment, making it impossible for discerning readers to test the obvious possibility that the ills were caused by the antiretroviral drugs rather than by the “HIV”: All antiretroviral drugs have notably toxic “side” effects (section 5 and particularly 5.3 in The Case against HIV).
What’s more, prominent pundits like specialist medical correspondents at prominent media fail to understand this elementary point. Here’s a recent illustration brought to my attention by an independent investigative journalist who directs the Washington Center for Politics & Journalism:
“The chief New York Times HIV-AIDS Industry propagandist, Donald G. McNeil, Jr. has struck again, re-writing another Industry press release.
Heart Problems Linked to Those Born With H.I.V.
Donald has really outdone himself this time. Read the first paragraph of his story: ‘Children born with HIV are more likely to have heart problems later in life, even if they are treated early with antiretroviral drugs, a recent study has found’.
Now, read it again and pay extra close attention to these words: ‘…even if they are treated early with antiretroviral drugs.’
Even if !!! How could anybody–even Donald–be so dense as to miss the point that it’s the drugs, stupid, that cause the heart problems!
If it weren’t so serious, it would be funny.
Here’s the link to the ‘study’ which does at least allude to the role of the ARV’s….”
In fact, that original article acknowledges quite plainly that at least part of the cardiovascular risk stems from the antiretroviral drugs: “increased aggregate atherosclerotic CVD risk factor burden . . . [was] predicted by HIV disease severity and boosted protease inhibitor use . . . .
prolonged exposure to HIV and highly active antiretroviral therapy (HAART) has been associated with long-term complications. Atherosclerotic cardiovascular disease (CVD) risk factors, including hyperlipidemia, lipodystrophy, diabetes, and hypertension have increased in prevalence and severity with the advent of HAART.” [emphases added].
McNeil’s NY Times piece fails to acknowledge this significant aspect of the original article, which even mentions a dose-response effect of the antiretroviral drugs: “risk factor burden . . . . included longer duration of use of a ritonavir-boosted protease inhibitor” [emphasis added].
Failure to emphasize the harm done to babies by antiretroviral drugs is particularly culpable because it seems to be becoming fashionable to believe that “HIV-positive” babies can be “cured” by early intensive antiretroviral treatment (Early treatment is found to clear H.I.V. in a 2nd baby). Yet it has been known for decades that “HIV-positive” babies are most likely just carrying “HIV” antibodies transferred from the mother, and most “HIV-positive” newborns spontaneously revert to “HIV”-negative within a year (pp. 97-9 in The Origin, Persistence and Failings of HIV/AIDS Theory).
This entry was posted on 2014/03/06 at 11:50 am and is filed under antiretroviral drugs, experts, HIV absurdities, HIV does not cause AIDS, HIV in children, HIV skepticism, HIV tests, HIV transmission, uncritical media. Tagged: antiretroviral drugs cause heart disease, antiretroviral treatment for babies, cure for HIV. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
David Crowe said
Read: http://aras.ab.ca/haart-heart.php
Henry Bauer said
David Crowe:
THANKS, we’re adding that web-page to the sources cited in The Case against HIV
prkralex said
Recently Merck has started patient enrollment in its global Phase III clinical trial ‘ONCEMRK’, which is evaluating a once-daily investigational formulation of Isentress (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults.
Henry Bauer said
prkralex:
Yes, “HIV” is a blockbuster profit-maker for the drug industry